A review on the current drugs and new targets for obesity
DOI:
https://doi.org/10.18231/j.joapr.2019.v.8.i.1.002Keywords:
Obesity, Diet, BMI, weight gainAbstract
Obesity is defined as the condition in which the Body Mass Index (BMI) of an individual is between 25 and 29.5 that is ≥30kg/m2 and is caused by the imbalance management of energy intake and expenditure. Obesity is among the most prevalent diseases in the world and approximately over 10% of the people belong to overweight group in the world and over 5% in India. Currently many drugs are used to treat or to manage obesity. But these drugs also account for several side effects. So there is an extensive need of promising drugs which can control obesity with greater efficacy and economic viability. This review focusses on the current drugs in the market used to treat obesity and also few of the new probable targets to discover drugs
Downloads
References
Mohamed GA, Ibrahim SRM, Elkhayat ES, El Dine RS. Natural anti-obesity agents. Bull. Fac. Pharmacy, Cairo Univ., 52, 269–84 (2014).
Oh S, Kim K, Chung Y, Shong M, Park S. Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities. Curr. Top. Med. Chem., 9, 466–81 (2009).
Hatware KV, Sharma S, Patil K, Shete M, Karri S, Gupta G. Evidence for gastroprotective, anti-inflammatory and antioxidant potential of methanolic extract of Cordia dichotoma leaves on indomethacin and stress induced gastric lesions in Wistar rats. Biomed. Pharmacother., 103, 317–25 (2018).
World health organization. “Obesity and overweight.” : <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight, cited 01 April, 2020.
World Rankings. “Obesity Rates by Country (July 2017).” : <https://renewbariatrics.com/obesity-rank-by-countries/ cited 01 April, 2020
Redinger RN (2007). The pathophysiology of obesity and its clinical manifestations. Gastroenterology & hepatology, 3(11), 856.
Food and Drug Administration. “Orlistat nonprescription briefing document: NDA 21– 887. Endocrine and metabolic drugs advisory committee meeting, January 23, 2006.”: <http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4201B1_02_03-FDA-Clinical-Review.Pdf. cited on 21 January, 2020
Xia Y, Kelton CML, Guo JJ, Bian B, Heaton PC. Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010. Obesity, 23, 1721–8 (2015).
Sternson SM, Eiselt A-K. Three Pillars for the Neural Control of Appetite. Annu. Rev. Physiol., 79, 401–23 (2017).
Muppala S, Konduru SKP, Merchant N, Ramsoondar J, Rampersad CK, Rajitha B, Mukund V, Kancherla J, Hammond A, Barik TK, Mannarapu M, Alam A, Basha R, Bramhachari PV, Verma D, Sushma PS, Pattnaik S, Nagaraju GP. Adiponectin: Its role in obesity-associated colon and prostate cancers. Crit. Rev. Oncol. Hematol., 116, 125–33 (2017).
Nagaraju GP, Aliya S, Alese OB. Role of adiponectin in obesity related gastrointestinal carcinogenesis. Cytokine Growth Factor Rev., 26, 83–93 (2015).
Rodgers RJ, Tschop MH, Wilding JPH. Anti-obesity drugs: past, present and future. Dis. Model. Mech., 5, 621–6 (2012).
Zhang Y, Liu J, Yao J, Ji G, Qian L, Wang J, Zhang G, Tian J, Nie Y, Zhang Y, Gold M, Liu Y. Obesity: Pathophysiology and Intervention. Nutrients, 6, 5153–83 (2014).
Han L-K, Xu B-J, Kimura Y, Zheng Y, Okuda H. Platycodi Radix Affects Lipid Metabolism in Mice with High Fat Diet–Induced Obesity. J. Nutr., 130, 2760–4 (2000).
Asai A, Miyazawa T. Dietary Curcuminoids Prevent High-Fat Diet–Induced Lipid Accumulation in Rat Liver and Epididymal Adipose Tissue. J. Nutr., 131, 2932–5 (2001).
Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Stohs SJ. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). Mol. Cell. Biochem., 238, 89–103 (2002).
Shin J-E, Han MJ, Kim D-H. 3-Methylethergalangin Isolated from Alpinia officinarum Inhibits Pancreatic Lipase. Biol. Pharm. Bull., 26, 854–7 (2003).
KWON C-S, SOHN HY, KIM SH, KIM JH, SON KH, LEE JS, LIM JK, KIM J-S. Anti-obesity Effect of Dioscorea nipponica Makino with Lipase-inhibitory Activity in Rodents. Biosci. Biotechnol. Biochem., 67, 1451–6 (2003).
Han L-K, Sumiyoshi M, Zheng Y-N, Okuda H, Kimura Y. Anti-obesity action ofSalix matsudana leaves (Part 2). Isolation of anti-obesity effectors from polyphenol fractions ofSalix matsudana. Phyther. Res., 17, 1195–8 (2003).
Zhao HL, Kim YS. Determination of the kinetic properties of platycodin D for the inhibition of pancreatic lipase using a 1,2-diglyceride-based colorimetric assay. Arch. Pharm. Res., 27, 1048–52 (2004).
Cha Y-S, Rhee S-J, Heo Y-R. Acanthopanax senticosus Extract Prepared from Cultured Cells Decreases Adiposity and Obesity Indices in C57BL/6J Mice Fed a High Fat Diet. J. Med. Food, 7, 422–9 (2004).
Shin J-E, Han MJ, Song M-C, Baek N-I, Kim D-H. 5-Hydroxy-7-(4′-hydroxy-3′-methoxyphenyl)-1-phenyl-3-heptanone: A Pancreatic Lipase Inhibitor Isolated from Alpinia officinarum. Biol. Pharm. Bull., 27, 138–40 (2004).
Ninomiya K, Matsuda H, Shimoda H, Nishida N, Kasajima N, Yoshino T, Morikawa T, Yoshikawa M. Carnosic acid, a new class of lipid absorption inhibitor from sage. Bioorg. Med. Chem. Lett., 14, 1943–6 (2004).
Kumar A, Vimalavathini R. Possible anorectic effect of methanol extract of Benincasa hispida (Thunb). Cogn, fruit. Indian J Pharmacol., 36, 348-50 (2004)
Lee I-A, Lee JH, Baek N-I, Kim D-H. Antihyperlipidemic Effect of Crocin Isolated from the Fructus of Gardenia jasminoides and Its Metabolite Crocetin. Biol. Pharm. Bull., 28, 2106–10 (2005).
Han L-K, Zheng Y-N, Yoshikawa M, Okuda H, Kimura Y. Anti-obesity effects of chikusetsusaponins isolated from Panax japonicus rhizomes. BMC Complement. Altern. Med., 5, 9 (2005).
Leibel RL, Seeley RJ, Darsow T, Berg EG, Smith SR, Ratner R. Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium. Diabetes, 64, 2299–309 (2015).
Ochner CN, Tsai AG, Kushner RF, Wadden TA. Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations. Lancet Diabetes Endocrinol., 3, 232–4 (2015).
Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr. Pract., 22, 1–203 (2016).
Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity, 21, 935–43 (2013).
Wadden TA, Butryn ML, Hong PS, Tsai AG. Behavioral Treatment of Obesity in Patients Encountered in Primary Care Settings. JAMA, 312, 1779 (2014).
Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9•1 million participants. Lancet, 377, 557–67 (2011).
Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes., 27, 1437–46 (2003).
Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ, 335, 1194–9 (2007).
Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, Krishnan KRR. Bupropion for Weight Loss: An Investigation of Efficacy and Tolerability in Overweight and Obese Women. Obes. Res., 9, 544–51 (2001).
United States Food and Drug administration (2010). “FDA reduction Document: NDA 200063: Contrave (Naltrexone 4 mg, 8 mg/Bupropion HCL 90 mg Extended Release Tablet)” < https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000ClinPharmR.pdf, Cited on 20 december, 2019.
Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination Therapy of Zonisamide and Bupropion for Weight Reduction in Obese Women. J. Clin. Psychiatry, 68, 1226–9 (2007).
Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-Analysis: Pharmacologic Treatment of Obesity. Ann. Intern. Med., 142, 532 (2005).
Haddock C, Poston W, Dill P, Foreyt J, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes., 26, 262–73 (2002).
Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet, 377, 1341–52 (2011).
Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). Obesity, 20, 330–42 (2012).
Padwal R, Li S, Lau D. Long-term pharmacotherapy for obesity and overweight. The Cochrane Database of Systematic Reviews (Protocol). John Wiley & Sons, Ltd, Chichester, UK, (2002).
Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet, 370, 1706–13 (2007).
O’Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR. Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. Obesity, 20, 1426–36 (2012).
Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM. A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial. J. Clin. Endocrinol. Metab., 96, 3067–77 (2011).
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N. Engl. J. Med., 373, 11–22 (2015).
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med., 373, 2117–28 (2015).
Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int. J. Obes., 31, 494–9 (2007).
Kopelman P, de Groot HG, Rissanen A, Rossner S, Toubro S, Palmer R, Hallam R, Bryson A, Hickling RI. Weight Loss, HbA 1c Reduction, and Tolerability of Cetilistat in a Randomized, Placebo-controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical). Obesity, 18, 108–15 (2010).
Kim DD, Krishnarajah J, Lillioja S, de Looze F, Marjason J, Proietto J, Shakib S, Stuckey BGA, Vath JE, Hughes TE. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes, Obes. Metab., 17, 566–72 (2015).
Londono Lemos ME. Pharmacological Advances to the Treatment of Obesity. J. Child. Obes., 03, (2018).
Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst. Rev., (2016).
Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers. J. Clin. Pharmacol., 35, 1103–8 (1995).
Xenical information. “Xenical (orlistat) patient information. South SanFrancisco (CA). Genentech USA, Inc.; c2016” :
<https://www.aace.com/files/obesity/toolkit/ xenical_patient_info.pdf. cited 01 January 2020
Yanovski SZ, Yanovski JA. Long-term Drug Treatment for Obesity. JAMA, 311, 74 (2014).
Bray GA, Ryan DH. Medical Therapy for the Patient With Obesity. Circulation, 125, 1695–703 (2012).
Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-Analysis: Pharmacologic Treatment of Obesity. Ann. Intern. Med., 142, 532 (2005).
Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes., 27, 1437–46 (2003).
Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27, 155–61 (2004).
Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab., 28, 437–45 (2002).
The US Food and Drug Administration. “FDA drug safety communication. Silver Spring (MD): Belviq, The US Food and Drug Administration; c2020” <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market cited on 16 February, 2020
Spreitzer H, "Lorcaserin". Österreichische Apothekerzeitung (in German), 19, 1083-64 (2010).
Millan MJ. Serotonin 5-HT2C Receptors as a Target for the Treatment of Depressive and Anxious States: Focus on Novel Therapeutic Strategies. Therapies, 60, 441–60 (2005).
Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Thomsen WJ, Saldana HR, Whelan KT, Menzaghi F, Webb RR, Beeley NRA. Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity. Bioorg. Med. Chem. Lett., 15, 1467–70 (2005).
O’Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR. Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. Obesity, 20, 1426–36 (2012).
Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM. A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial. J. Clin. Endocrinol. Metab., 96, 3067–77 (2011).
Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, Underwood P, Park K-H, Seufert J, Kang ES, Sternthal E, Karagiannis A, Mantzoros CS. Pharmacotherapy of type 2 diabetes: An update. Metabolism, 78, 13–42 (2018).
Farr OM, Tsoukas MA, Triantafyllou G, Dincer F, Filippaios A, Ko B-J, Mantzoros CS. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study. Metabolism, 65, 945–53 (2016).
Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Drent ML, Diamant M, IJzerman RG. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes. Diabetes Care, dc150772 (2015).
Lean MEJ, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, Astrup A. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int. J. Obes., 38, 689–97 (2014).
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N. Engl. J. Med., 373, 11–22 (2015).
Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, Filippaios A, Bowers J, Srnka A, Gavrieli A, Ko B-J, Liakou C, Kanyuch N, Tseleni-Balafouta S, Mantzoros CS. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled. Diabetologia, 59, 954–65 (2016).
Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obes. Metab., 8, 436–47 (2006).
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care, 32, 84–90 (2009).
Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet, 374, 1606–16 (2009).
Tak YJ, Lee SY. Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. World J. Mens. Health, 38, (2020).
Rothman RB, Baumann MH. Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy. Am. J. Ther., 16, 354–64 (2009).
Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann. N. Y. Acad. Sci., 1411, 106–19 (2018).
Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate Reduces Energy and Fat Gains in Lean ( Fa/? ) and Obese ( fa/fa ) Zucker Rats. Obes. Res., 8, 656–63 (2000).
Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int. J. Obes., 26, 344–53 (2002).
Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate. J. Hypertens., 32, 1178–88 (2014).
Information on qsymia. “qsymia full prescribing information” : <https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf, cited on 01 April, 2020.
Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O’Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA. Rational Design of a Combination Medication for the Treatment of Obesity. Obesity, 17, 30–9 (2009).
Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 100, 342–62 (2015).
United States Food and Drug Administration (2010). “FDA Briefing Document: NDA 200063: Contrave (Naltrexone 4 mg, 8 mg/Bupropion HCL 90 mg Extended Release Tablet)” : < https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000MedR.pdf, Cited on 01 April, 2020.
United States Food and Drug Administration (2014). “Center for Drug Evaluation and Research. NDA 200063 Orig1s000” : <https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000SumR.pdf, Cited on 02 April, 2020.
European Medicines Agency. “Mysimba Summary of Product Characteristics” : <https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba, Cited on 02 April, 2020.
George M, Rajaram M, Shanmugam E. New and Emerging Drug Molecules Against Obesity. J. Cardiovasc. Pharmacol. Ther., 19, 65–76 (2014).
Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, Riboulet W, Funk J, Hertel C, Belli S, Sebokova E, Conde-Knape K, Konkar A, Drucker DJ, Gelfanov V, Pfluger PT, Müller TD, Perez-Tilve D, DiMarchi RD, Tschöp MH. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med., 21, 27–36 (2015).
Rodgers RJ, Tschop MH, Wilding JPH. Anti-obesity drugs: past, present and future. Dis. Model. Mech., 5, 621–6 (2012).
Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes., 30, S13–8 (2006).
Cluny NL, Chambers AP, Vemuri VK, Wood JT, Eller LK, Freni C, Reimer RA, Makriyannis A, Sharkey KA. The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol. Biochem. Behav., 97, 537–43 (2011).
Kang JG, Park C-Y. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab. J., 36, 13 (2012).
Randall PA, Vemuri VK, Segovia KN, Torres EF, Hosmer S, Nunes EJ, Santerre JL, Makriyannis A, Salamone JD. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol. Biochem. Behav., 97, 179–84 (2010).
Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat. Med., 19, 1252–63 (2013).
Wang QA, Tao C, Gupta RK, Scherer PE. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat. Med., 19, 1338–44 (2013).
Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481, 463–8 (2012).
Romeo GR, Lee J, Shoelson SE. Metabolic Syndrome, Insulin Resistance, and Roles of Inflammation – Mechanisms and Therapeutic Targets. Arterioscler. Thromb. Vasc. Biol., 32, 1771–6 (2012).
Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med., 18, 363–74 (2012).
Lee B-C, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim. Biophys. Acta - Mol. Basis Dis., 1842, 446–62 (2014).
Lumeng CN, DeYoung SM, Bodzin JL, Saltiel AR. Increased Inflammatory Properties of Adipose Tissue Macrophages Recruited During Diet-Induced Obesity. Diabetes, 56, 16–23 (2007).
Kim M-S, Yamamoto Y, Kim K, Kamei N, Shimada T, Liu L, Moore K, Woo JR, Shoelson SE, Lee J. Regulation of Diet-Induced Adipose Tissue and Systemic Inflammation by Salicylates and Pioglitazone. PLoS One, 8, e82847 (2013).
Rotkvic V, Altabas V. Anti-ghrelin antibodies in appetite suppression: recent advances in obesity pharmacotherapy. ImmunoTargets Ther., 123 (2015).
Monteiro MP. Obesity vaccines. Hum. Vaccin. Immunother., 10, 887–95 (2014).
Yamada T, Hara K, Kadowaki T. Association of Adenovirus 36 Infection with Obesity and Metabolic Markers in Humans: A Meta-Analysis of Observational Studies. PLoS One, 7, e42031 (2012).
Published
How to Cite
Issue
Section
Copyright (c) 2020 M J Poojashree, H S Siddalingaprasad, B R Swetha , Shivukumar Swamy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
